Exenatide News and Research

RSS
Exenatide (marketed as Byetta) is one of a new class of medications (incretin mimetics) approved for the treatment of diabetes mellitus type 2.
Amylin Pharmaceuticals to present new data from its obesity program at Obesity 2009

Amylin Pharmaceuticals to present new data from its obesity program at Obesity 2009

Intarcia's ITCA 650 phase 2 study in type 2 diabetes begins patient enrollment

Intarcia's ITCA 650 phase 2 study in type 2 diabetes begins patient enrollment

Amylin and Biocon collaborate to develop a peptide therapeutic for treating diabetes

Amylin and Biocon collaborate to develop a peptide therapeutic for treating diabetes

Synco Bio to manufacture Versartis type 2 diabetes drug candidate

Synco Bio to manufacture Versartis type 2 diabetes drug candidate

NDA for Exenatide once weekly accepted for FDA review

NDA for Exenatide once weekly accepted for FDA review

Diabetes drug exenatide promotes weight loss when added to diet and exercise

Diabetes drug exenatide promotes weight loss when added to diet and exercise

Novel diabetes treatment Syncria (albiglutide) improves glucose control and reduces weight

Novel diabetes treatment Syncria (albiglutide) improves glucose control and reduces weight

Amylin, Lilly update on FDA review of Byetta (exenatide) injection monotherapy submission

Amylin, Lilly update on FDA review of Byetta (exenatide) injection monotherapy submission

Expensive new diabetes drugs don't necessarily produce better outcomes

Expensive new diabetes drugs don't necessarily produce better outcomes

Once a week treatment for type 2 diabetes in the pipeline

Once a week treatment for type 2 diabetes in the pipeline

Advances in the management of diabetes mellitus

Advances in the management of diabetes mellitus

Benefit of exenatide has not yet been proven

Benefit of exenatide has not yet been proven

New drug application for exenatide has been accepted for review

New drug application for exenatide has been accepted for review

New drug application for regulatory approval of exenatide for the treatment of type 2 diabetes

New drug application for regulatory approval of exenatide for the treatment of type 2 diabetes

Exenatide shows significant improvements in glucose control for people With type 2 diabetes

Exenatide shows significant improvements in glucose control for people With type 2 diabetes